NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Titel:
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Auteur:
Bonvalot, Sylvie Rutkowski, Piotr L Thariat, Juliette Carrère, Sébastien Ducassou, Anne Sunyach, Marie-Pierre Agoston, Peter Hong, Angela Mervoyer, Augustin Rastrelli, Marco Moreno, Victor Li, Rubi K Tiangco, Béatrice Herraez, Antonio Casado Gronchi, Alessandro Mangel, László Sy-Ortin, Teresa Hohenberger, Peter de Baère, Thierry Le Cesne, Axel Helfre, Sylvie Saada-Bouzid, Esma Borkowska, Aneta Anghel, Rodica Co, Ann Gebhart, Michael Kantor, Guy Montero, Angel Loong, Herbert H Vergés, Ramona Lapeire, Lore Dema, Sorin Kacso, Gabriel Austen, Lyn Moureau-Zabotto, Laurence Servois, Vincent Wardelmann, Eva Terrier, Philippe Lazar, Alexander J Bovée, Judith V M G Le Péchoux, Cécile Papai, Zsusanna